FAB Stock Overview
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Fusion Antibodies plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.037 |
| 52 Week High | UK£0.50 |
| 52 Week Low | UK£0.03 |
| Beta | 0.44 |
| 1 Month Change | -5.06% |
| 3 Month Change | -16.67% |
| 1 Year Change | -88.97% |
| 3 Year Change | -97.61% |
| 5 Year Change | -95.59% |
| Change since IPO | -96.96% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation
Aug 31
Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation
Jan 25We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth
May 09Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%
Mar 17Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth
Jan 04Shareholder Returns
| FAB | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -1.3% | 1.9% | 2.3% |
| 1Y | -89.0% | -41.7% | 0.6% |
Return vs Industry: FAB underperformed the UK Life Sciences industry which returned -41.1% over the past year.
Return vs Market: FAB underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| FAB volatility | |
|---|---|
| FAB Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: FAB's share price has been volatile over the past 3 months.
Volatility Over Time: FAB's weekly volatility has decreased from 24% to 7% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 48 | Adrian Kinkaid | www.fusionantibodies.com |
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies.
Fusion Antibodies plc Fundamentals Summary
| FAB fundamental statistics | |
|---|---|
| Market cap | UK£3.58m |
| Earnings (TTM) | -UK£2.84m |
| Revenue (TTM) | UK£1.58m |
2.3x
P/S Ratio-1.3x
P/E RatioIs FAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAB income statement (TTM) | |
|---|---|
| Revenue | UK£1.58m |
| Cost of Revenue | UK£1.70m |
| Gross Profit | -UK£117.00k |
| Other Expenses | UK£2.72m |
| Earnings | -UK£2.84m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | -7.41% |
| Net Profit Margin | -179.67% |
| Debt/Equity Ratio | 0% |
How did FAB perform over the long term?
See historical performance and comparison